HOXA1 and hepatocellular carcinoma: A clinical trial (NCT03628651) has proposed and validated that multitarget HCC panels (HOXA1, EMX1, TSPYL5, B3GALT6, AFP, and AFP-L3) are more sensitive at detecting HCC at any stage than the GALAD score and AFP alone [89, 90].